| Literature DB >> 23044603 |
J E Wyatt1, W L Pettit, S Harirforoosh.
Abstract
With the beginning of the Human Genome Project, an emerging field of science was brought to the forefront of the pharmaceutical community. Pharmacogenetics facilitates optimization of the current patient-centered care model and pharmacotherapy as a whole. Utilizing these ever-expanding branches of science to nonsteroidal anti-inflammatory drugs (NSAIDs) can provide novel opportunities to affect patient care. With a wide range of NSAID choices available as treatment options for relieving pain and/or reducing inflammation or fever, a more systematic way of selecting the ideal agent for the patients based upon their genetic information could spare them from a potentially permanent health-care condition. Furthermore, if a patient possesses or lacks certain alleles, serious adverse events can be anticipated and avoided. The tailoring of drug therapy can be achieved using the published data and cutting-edge genetic testing to attain a higher standard of care for patients.Entities:
Mesh:
Substances:
Year: 2012 PMID: 23044603 DOI: 10.1038/tpj.2012.40
Source DB: PubMed Journal: Pharmacogenomics J ISSN: 1470-269X Impact factor: 3.550